Abstract

Cyclo-Gly-Pro (CGP) attenuates nociception, however its effects on salivary glands remain unclear. In this study, we investigated the acute effects of CGP on salivary flow and composition, and on the submandibular gland composition, compared with morphine. Besides, we characterized the effects of naloxone (a non-selective opioid receptor antagonist) on CGP- and morphine-induced salivary and glandular alterations in mice. After that, in silico analyses were performed to predict the interaction between CGP and opioid receptors. Morphine and CGP significantly reduced salivary flow and total protein concentration of saliva and naloxone reverted these alterations. The in silico docking analysis demonstrated the interaction of polar contacts between the CGP and opioid receptor Cys219 residue. Altogether, we showed that salivary hypofunction and glandular changes elicited by CGP may occur through opioid receptor suggesting that the blockage of opioid receptors in superior cervical and submandibular ganglions may be a possible strategy to restore salivary secretion while maintaining antinociceptive action due its effects on the central nervous system.
**Introduction**

Saliva exerts multiple functions in the oral cavity such as protection against microorganisms, contribution to the taste and digestion and maintenance of oral health [1–3]. Salivary function is controlled by sympathetic and parasympathetic nervous system, which innervate acinar, ductal, myoepithelial and vascular cells in salivary glands [4,5]. The activation of muscarinic receptors in the acinar cells is the most important control of salivary flow rates [6]. Electrical stimulation of sympathetic efferent branch to the salivary glands results in a low flow of saliva which is rich in proteins [7]. Paradoxically, sympathectomy also generates decrease in salivary flow [8]. These findings demonstrate the complexity of the sympathetic regulation on salivary flow and salivary composition [9]. The activation of central pathways develops a great part in salivatory effects of intraperitoneal pilocarpine in rats [10].

Several substances with pharmacological properties can promote changes in salivary function. Morphine is an opioid receptor agonist that plays intense and long-lasting analgesia [11,12]. It was demonstrated that morphine increase lactate levels in serum, however its effects on salivary lactate concentration are unknown [13]. In humans and rats, the morphine administration was correlated to hyposalivation, and associated with changes in the ionic composition [14–15]. Bearing in mind that amylase is the most abundant protein in saliva [16], salivary amylase concentration decreased after morphine treatment [17]. It has been clearly demonstrated that morphine promotes reduction in the sympathetic activity to salivary glands by its action on the superior cervical ganglion and by inhibiting the release of neurotransmitter from postganglionic nerve endings [17]. Additionally, kappa-, delta-, and mu-opioid-receptor agonists are able to inhibit L-, N- and P/Q-types of calcium channels in submandibular ganglion neurons, indicating a reduction in parasympathetic activity to salivary glands [18]. The reduction on the parasympathetic nerve-induced salivary secretion generated by the morphine was partially reversed by naloxone, a non-selective opioid receptor antagonist. However, salivary secretion stimulated by intravenous infusion of acetylcholine was not reduced by morphine [19].

Cyclic dipeptides are among the smallest peptide derivatives frequently found in nature [20]. Cyclo-Gly-Pro (CGP) is an endogenous diketopiperazine derived from N-terminal tripeptide, glycine-proline-glutamate which is naturally cleaved from the insulin-like growth factor 1 (IGF-1) [21,22]. Previous studies have shown that CGP induces neuroprotective effects after ischemic brain injury [22]. CGP 35348 has an adjuvant role to produce a dose-dependent antagonism of antinociception [23]. Recently, our group demonstrated that the antinociceptive effect of CGP seemed to be mediated by the interaction with the opioid system, also reducing the hyper nociception and paw inflammation induced by carrageenan [24]. This might indicate the potential of CGP as a candidate for antinociceptive role with fewer side effects on salivary glands. It is important to emphasize that several effects of CGP in oral territories remain unknown.

Despite the knowledge about the effect of pharmacological agents on salivary glands, and consequently on salivary secretion, the CGP capacity to modulate submandibular and salivary components has never been investigated. Besides, it is important to highlight that the interaction between CGP and opioid receptors has also not been demonstrated. Thus, the aims of the present study were to investigate the CGP acute effects on salivary flow and composition, and on submandibular gland composition compared with morphine. Besides, we characterized the naloxone (a non-selective opioid receptor antagonist) effect on CGP- and morphine-induced salivary and glandular alterations in mice. After that, in silico analyses were performed to predict the 3D-interaction between the CGP and opioid receptors.
Materials and methods

This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Brazilian Society of Laboratory Animals Science (SBCAL). Experimental procedures were approved by the Ethical Committee of the Federal University of Alagoas (UFAL) (License 065/2011), according to Ethical Principles adopted by the Brazilian College of Animal Experimentation (COBEA). Animal studies are reported in compliance with the approved guidelines. To minimize the number of animals used and their suffering all effort were taken. Male Swiss mice (Mus musculus, 2 months) weighing 25–36 g were obtained from the breeding colonies of the UFAL and maintained at the Institute of Biological Sciences and Health rodent housing facility. Mice were randomly assigned to standard cages with five animals per cage. Animals were allowed free access to water and standard rodent chow diet and kept at 22 ± 2˚C with a 12 h light/dark cycle, light on at 07:00h. To minimize circadian effects, all experimental procedures were conducted during the light phase. Power analysis was used as a basis to set the number of animals per experiment [25]. The number of samples was insert in each legend.

Materials

All used reagents were of analytical grade and used without further purification. The following reagents were used: cyclo-Gly-Pro (CGP, ≥ 98% purity; Catalog number: 3705-27-9), morphine solution, naloxone and phosphate-buffered saline (Sigma Chemical Co., St. Louis, MO, USA).

Experimental procedures

Animals were treated with vehicle (NaCl, 0.9%), morphine or CGP (CGP, ≥ 98% purity) (Fig 1, Protocol 1). Morphine was applied at dose of 17.5 μmol kg⁻¹ (0.1 ml/10g, i.p.) and CGP 1 μmol kg⁻¹ (0.1 ml/10g, i.p.), considering the similar antinociceptive effects observed in the hot plate test [24]. For randomization, vehicle was injected in the control group, while the other mice received morphine or CGP. Blinding was implemented as follows: the operator was blinded to the group identity, but not to animals of the same group. Thus, for i.p. drug injection, different solutions were prepared: vehicle, morphine and CGP. In order to analyze the opioid receptors involvement in salivary secretion and changes in submandibular composition, similar analysis was performed in another set of animals under naloxone administration (pre-treatment)(15.3 μmol kg⁻¹, i.p.), an opioid receptor antagonist, 15 minutes before treatment with vehicle, morphine or CGP (Fig 1, Protocol 2).

Saliva and salivary glands collection

One hour after treatment with vehicle, morphine or CGP, the animals were intraperitoneally anesthetized (xylazine 5 mg kg⁻¹ body weight; ketamine 35 mg kg⁻¹) and then parasympathetic stimulation was performed for salivary secretion through pilocarpine injection (2 mg kg⁻¹, i.p.). Total saliva was collected for 10 min from the oral cavity [26]. After that, submandibular and parotid glands were collected and weighted [27]. Salivary secretion was calculated based on volume of saliva acquired in 10 minutes collection divided by the weight of the salivary gland tissues (μl/g tissue) (Fig 1).

Total protein concentration of saliva

Total protein concentration was measured using Bradford Protein assay. Values were expressed in mg/ml using serum albumin as standard protein. [28].
Saliva analysis by dispersive x-ray analysis system (EDX)

Pilocarpine-stimulated saliva from Protocol 1 animals was used to assess the inorganic elements by EDX (Fig 1). In each experiment, 15 μL of saliva were used to measure the ionic composition. EDX mode was set up as 180 seconds per sample ion detection using Si (Li) semiconductor detector (Shimadzu, Fukuoka, Japan) at 30 kV in a vacuum chamber. Ions quantification was taken from the excitement of their electrons.

Lactate concentration of submandibular glands

Submandibular gland specimens were tested using an enzymatic system for lactate quantitative determination (Labtest, Brazil). Experiment was done according to the manufacturer's
The submandibular tissue was removed, washed using physiological saline (NaCl 0.9%), and immediately frozen at—80˚C. Frozen gland tissue was homogenized in a phosphate buffer (1 : 10 w/v, pH 7.4). To measure the lactate concentration, the homogenate (25 μg) was incubated in a solution with 4- aminoantipyrine (50 mmol/L), peroxidase, L-lactate oxidase (1,000 U/L) e N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline (1.5 mmol/L) and sodium azide (0.09%) at 37˚C for 5 minutes using a spectrophotometer at 340 nm.

**Histology**

The histological analysis in submandibular glands were performed only in animals described in protocol 1 (Fig 1). Submandibular glands were fixed in 10% buffered formalin. Subsequently, these glands were dehydrated in alcohol (80, 90 and 100%), cleared in xylene and embedded in paraffin. Histological sections with a thickness of 5 μm were acquired using a microtome (Leica RM2125). Then these sections were placed on slides and stained with hematoxylin and eosin. Histological slides were examined and micrograph pictures were obtained using an optical microscope (Olympus BX41).

**Acetylcholinesterase activity of submandibular glands**

The acetylcholinesterase (AChE) activity quantification in submandibular glands were performed only in animals described in protocol 1 (Fig 1) using a acetylcholine as substrate (Ach, Sigma Chemical, St. Louis, Mo, USA) at room temperature. The submandibular glands were homogenized in saline (1:10, 0.9%), through a tissue shredder (Polytron ®). In a 96-well plate, acetylcholine (50μL) was added, and then color reagent was added and taken to incubator for 3 minutes at 37˚C. Subsequently, sample (20μL) was added [the first well received deionized water (20μL) and the second the standard solution (20μL)] and then taken back to the water bath for 2.5 minutes at 37˚C. Finally, a blocked solution (150μL) was added for subsequent reading at the spectrophotometer (at absorbance 410nm). The AChE activity was determined by the sample value product. Enzyme activity values were calculated after normalization by a total protein concentration measured using Bradford assay.

**Molecular profile in submandibular glands by ATR-FTIR spectroscopy**

Submandibular glands spectra were recorded in 4000–400 cm⁻¹ region using FTIR spectrophotometer Vertex 70 (Bruker Optik) using a micro-attenuated total reflectance (ATR) accessory. The fingerprint region was chosen to be displayed due to the interest region. All spectra were recorded at room temperature (23±1˚C). The crystal material unit in ATR unit was a diamond disc as internal-reflection element. The sample penetration depth ranges between 0.1 and 2 μm and depends on the wavelength and the refractive index of the ATR-crystal material. In the ATR-crystal the infrared beam is reflected at the interface toward the sample. Twenty mg of submandibular were lyophilized using a rotary evaporator (Thermo Savant, San Jose, CA) to obtain sample spectra. The air spectrum was used as a background in ATR-FTIR analysis. Samples spectrum were taken with 4 cm⁻¹ of resolution and 32 scans were performed to each analysis. The ATR-FTIR spectra were also baseline corrected using OPUS software [29]. Table 1 shows the frequencies and assignments of the vibrational modes identified in submandibular glands. Briefly, the vibrational mode between 1687–1594 cm⁻¹ is identified as υ_\text{NH} (Amide I) bending vibrations [29–31]. The δ_\text{NH} (Amide II) bending vibration is usually represented between 1594-1494cm⁻¹ [29,32]. The vibrational modes between 1488–1433 cm⁻¹ are attributed to CH₂/CH₃ vibrations. The band between 1432–1365 cm⁻¹ demonstrates CO groups (ester) stretching vibrations. Besides, spectral area between 1290–1185 cm⁻¹ indicates PO₂ asymmetric [29]. The 1135–999 cm⁻¹ spectral area corresponds PO₂ symmetric [29].
Cyclo-Gly-Pro (CGP) and opioid receptor (OR) structure assembly and interaction

The human Opioid Receptor protein FASTA sequence (Homo sapiens, access number in Gene Bank: AAA73958.1) was submitted online in I-TASSER server to predict and generate high-quality 3D predictions of this protein. The best model was verified using RAMPAGE: Assessment of the Ramachandran Plot, and Verify3D web tools to determine the spatial coherence and compatibility of the atomic model (3D) with its own amino acid sequence (1D). The CGP 3D structure was obtained from Pubchem (PubChem CID: 193540). After that, in silico analyses were performed to predict the interaction of both structures. AutoDOCK Vina [34] was used to predict the molecular docking using the Root-mean-square deviation of atomic positions (RMSd) and free energy calculations. PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC, was used to visualize the CGP-OP interactions and export image files.

Statistical analysis

In this study, data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology [35]. Values are presented as mean ± SEM. The heat map and analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA). Kolmorogov-Smirnov test was used to determine the normality of the sample distributions. Comparisons of results were performed by ANOVA, followed by Turkey’s or Dunnett’s post-test at P value <0.05.

Results

Effects of opioid receptors (OR) in salivary secretion and salivary composition

Salivary secretion was significantly reduced in morphine compared to vehicle (~15%; p <0.05). Similarly, CGP significantly decreased salivary secretion compared to vehicle (~20%, p <0.05). Differences in salivary secretion were not significant between morphine- and CGP-treated mice (Fig 2A). To confirm the effects of the opioid receptors, naloxone was administered before the treatment with vehicle, morphine or CGP. The pilocarpine-stimulated salivary secretion remained unchanged after naloxone administration in vehicle mice (p >0.05; Fig 2A). On the other hand, naloxone significantly increased the salivary secretion in mice treated with CGP and morphine (~20% and 30%, respectively; p <0.01) (Fig 2A).
In order to analyze the effects of CGP and morphine, total protein concentration in saliva was measured using Bradford assay. Total protein concentration in saliva significantly decreased ($p < 0.01$) when CGP (~45%) and morphine (~35%) was administrated and compared to vehicle (Fig 2B). Total protein concentration in saliva was similar ($p > 0.05$) in morphine and CGP-treated mice. The administration of naloxone in vehicle mice kept the total protein concentration stable ($p > 0.05$; Fig 2B). On the other hand, naloxone significantly increased the total protein concentration in saliva of mice treated with CGP and morphine (~40%; $p < 0.001$; Fig 2B).

Dispersive X-ray analysis was performed to analyze the CGP and morphine effects on the ionic composition in saliva. The composition of potassium, chloride, sodium and sulfur ions in saliva remained unchanged after acute treatment with morphine or CGP compared to vehicle (S1 Fig).
Maintenance of salivary glands weight under opioid receptors (OR) blockade

In order to investigate the CGP or morphine effects in salivary glands, the parotid and sub-mandibular glands were properly weighed. The results demonstrated that the glands weight remained unchanged after acute treatment with morphine or CGP (Table 2). As expected, the salivary glands weight also did not change with the naloxone pre-treatment (Table 2).

Histological changes of submandibular gland under opioid receptors (OR) blockade

To determine whether CGP promoted morphological and structural changes in salivary gland compared to the morphine treatment, we stained the submandibular sections with hematoxylin-eosin. The acinar cells, ductal cells and connective tissue remained unaltered (S2A Fig). However, submandibular glands histological analysis showed of evacuated spaces increased between serous and mucous acini in glandular parenchyma after one-hour treatment with morphine or CGP compared to the vehicle (S2B and S2C Fig).

Effects of opioid receptors (OR) blockade on lactate levels of submandibular glands

Morphine (~15%) and CGP (~15%) increased \( p < 0.001 \) lactate levels in submandibular gland compared to vehicle (Fig 3). Lactate levels in submandibular glands were similar \( p > 0.05 \) in morphine and CGP-treated mice. The lactate levels in submandibular gland remained unchanged after naloxone administration in vehicle mice \( p > 0.05 \); Fig 3). On the other hand, naloxone significantly decreased this parameter in mice treated with CGP and morphine \( (~20\%; \ p < 0.001) \) (Fig 3).

Effects of opioid receptors (OR) blockade on acetylcholinesterase activity in of submandibular glands

The acetylcholinesterase activity in submandibular gland was unaffected after acute treatment with morphine \( (0.16 \text{ UA/μg} \pm 0.02, \ p > 0.05) \) or CGP \( (0.15 \text{ UA/μg} \pm 0.02, \ p > 0.05) \) compared to vehicle \( (0.15 \text{ UA/μg} \pm 0.03) \). Besides, acetylcholinesterase activity in submandibular gland was similar \( p > 0.05 \) in morphine and CGP-treated mice (S3 Fig).

Table 2. Parotid and submandibular weights from vehicle-, morphine- or CGP-treated mice in the presence or absence of naloxone.

| Treatment          | Submandibular weight (mg) | Parotid weight (mg) |
|--------------------|---------------------------|---------------------|
| Vehicle            | 51.21 ± 2.81 (9)          | 28.42 ± 1.55 (9)    |
| Morphine           | 50.50 ± 3.05 (10)         | 34.44 ± 4.35 (10)   |
| CGP                | 49.01 ± 2.62 (10)         | 31.56 ± 3.11 (10)   |
| Naloxone+ Vehicle  | 50.20 ± 3.44 (6)          | 30.03 ± 5.38 (6)    |
| Naloxone+Morphine  | 50.98 ± 4.12 (6)          | 32.77 ± 5.69 (6)    |
| Naloxone+CGP       | 52.67 ± 5.39 (6)          | 31.22 ± 3.80 (6)    |

CGP, cyclo-Gly-Pro. \( p > 0.05 \) vs. vehicle. One-way ANOVA, Student-Newman-Keuls as post hoc test.

https://doi.org/10.1371/journal.pone.0229761.t002
Effects of opioid receptors (OR) blockade on chemical profile in submandibular by ATR-FTIR spectroscopy

The submandibular gland infrared spectrum is a superposition of several compounds and the absorption bands in ATR-FTIR spectrum intensities are directly proportional to the components concentration. The submandibular gland spectra of vehicle-, CGP- or morphine-treated animals in presence or absence of naloxone are represented in Fig 4A.

To understand better the response of proteins, phospholipids and lipids in submandibular gland under opioid receptors (OR) blockade, we analyzed the area of molecular components using ATR-FTIR spectroscopy. There are six major vibrational modes highlighted at 1635 cm\(^{-1}\) (1687–1594 cm\(^{-1}\)), 1550 cm\(^{-1}\) (1594–1494 cm\(^{-1}\)), 1450 cm\(^{-1}\) (1488–1433 cm\(^{-1}\)), 1400 cm\(^{-1}\) (1432–1365 cm\(^{-1}\)), 1232 cm\(^{-1}\) (1290–1185 cm\(^{-1}\)) and 1031 cm\(^{-1}\) (1135–999 cm\(^{-1}\)), confirming the presence of proteins, lipids, phospholipids and glycogen, according to the details showed for each peak, corresponding to the specific vibration molecules (Fig 4A). The vibrational modes between 1687–1594 cm\(^{-1}\) and 1594–1494 cm\(^{-1}\), representing amide I and amide II, respectively, were reduced in morphine- or CGP-treated mice. These changes were reversed by the pre-treatment with naloxone (Fig 4B and 4C). The vibrational modes between 1488–1433 cm\(^{-1}\) and 1432–1365 cm\(^{-1}\), representing CH\(_2\)/CH\(_3\) and C = O, respectively, were also reduced in morphine- or CGP-treated mice. These changes were also reversed by the pre-treatment with naloxone (Fig 4D and 4E). Besides, two vibrational modes at 1290–1185 and 1135–999 cm\(^{-1}\) were also reduced in morphine- or CGP-treated mice compare to the vehicle. These vibrational modes represent PO\(_2\) asymmetric and PO\(_2\) symmetric, respectively, and the naloxone pre-treatment reversed the changes in both submandibular glands components (Fig 4F and 4G). A heat map with the mean relative changes clearly demonstrates the expression in these vibrational modes (Fig 4H).

Assembly and interaction of the OR and CGP structure

In silico modeling of OR and molecular docking of OR and CGP were performed by I-TASSER server. Fig 5A shows the full cartoon structure of OP (green) interacting with CGP (red). The extended view of the interaction site from docking analysis demonstrated the polar contacts (yellow dashes) between the CGP (red) and the OR Cys219 residue (Fig 5B). Fig 5C shows the
full surface of the structure of OP (green) coupled with CGP (red) and Fig 5D presents the OP framework and conformational interaction site.

**Discussion**

The opioid agonist depressant mechanisms on salivary secretion and salivary glandular tissue effects remain unclear. Additionally, the potential effects of therapeutic agents in secondary target organs as salivary glands still need to be carefully investigated. Given the ongoing attempts to describe opioid side effects on salivary function, it is clearly important to understand and characterize the CGP effects in saliva and salivary glands composition compared with morphine. We showed that either CGP or morphine promoted the reduction in flow rates and in salivary protein concentration, increased lactate levels in glandular tissue and resulted in severe changes in chemical components in submandibular glands. Conversely, the naloxone (a non-selective opioid receptor antagonist) reversed this alteration in saliva and submandibular glands.

Human salivary secretion was decreased from 1 to 4 hours after administration of morphine intravenously [36]. Besides, the treatment with morphine (6 mg/kg) also inhibited the

---

**Fig 4.** Chemical compounds profile in submandibular gland represented by means of ATR-FTIR spectra of Swiss mice after acute treatment with vehicle, morphine or CGP in the presence or absence of naloxone. (A) ATR-FTIR spectra displayed in 1800–800 cm⁻¹ region. The major vibrational modes are represented, indicating changes under the acute treatment with CGP or morphine on the various chemical compounds present in the submandibular gland. These changes were reversed by naloxone pre-treatment. (B) Amide I (1687–1594 cm⁻¹), (C) Amide II (1594–1494 cm⁻¹), (D) CH₂/CH₃ (1488–1433 cm⁻¹), (E) C = O (1432–1365 cm⁻¹), (F) PO₂ asymmetric (1290–1185 cm⁻¹) and (G) PO₂ asymmetric (1135–999 cm⁻¹). (H) Heat map with the relative expression of each vibrational mode (Vehicle expression was set as 100%). Results are represented as mean ± SEM of 6 animals.

https://doi.org/10.1371/journal.pone.0229761.g004

**Fig 5.** Assembly and interaction of the OR and CGP structure. (A) Full cartoon structure of OP (green) coupled with CGP (red). (B) Expanded image of binding site from docking analysis. Polar contacts are shown by yellow dashes between the CGP (red) and the OR Cys219 residue. (C) Full surface structure of OP (green) coupled with CGP (red). (D) OP framework and conformational interaction site (green). The binding spot to CGP (red) is presented in orange.

https://doi.org/10.1371/journal.pone.0229761.g005
salivary flow in rats [14]. As expected, in this present study the acute treatment with morphine promoted salivary secretion reduction. Furthermore, for the first time, we showed that CGP also reduces salivary secretion in mice.

Previous studies have demonstrated that naloxone partially restores pilocarpine-stimulated and parasympathetic nerve stimulated-salivary secretion under morphine treatment [14,19]. As expected, our data corroborates previous studies demonstrating that naloxone reversed the morphine depressant effects in salivary flow. We further investigated whether the salivary flow changes elicited by CGP were also reversed by naloxone, due to its nonspecific antagonistic action on mu, kappa and delta opioid receptors [37]. It is important to point out that the opioid receptors blockage by naloxone was also able to reverse the inhibitory effect caused by CGP and to restore the salivary flow, indicating the CGP effect in opioid receptors as described to morphine treatment. So, these data suggest similar side effects on salivary glands by CGP or morphine.

Salivary ionic composition remained unchanged after acute treatment with CGP or morphine (5 mg kg$^{-1}$). In previous research, morphine at a dose of 25 mg kg$^{-1}$ did not alter the sodium and calcium concentrations in parotid saliva of rats; on the other hand, led to an increase in salivary potassium concentration [19]. Interestingly, morphine at a dose of 6 mg kg$^{-1}$ did not alter the presence of salivary potassium concentration, however it was able to reduce the salivary calcium and increase salivary sodium concentration [14]. It is possible that samples collected using different methods contributed to these different results. Despite the contradictory reports evaluating morphine effects on ions composition under lower and higher doses, our data on CGP showing no changes in salivary ionic composition has never been reported and suggests that CGP may not be involved in the regulation of several channels that regulate ionic composition in salivary glands.

We have also shown that CGP, as well as morphine, decreased salivary protein concentration in mice, which is corroborated elsewhere by the demonstration that an acute treatment with morphine (6 mg kg$^{-1}$) decreased protein concentration in saliva from the rat submandibular gland [14]. Considering that sympathetic activity on salivary glands is the most important control of salivary protein secretion and pointing out that the presence of opioid receptors in submandibular and parotid glands was never demonstrated, the CGP or morphine effects to reduce protein concentration in saliva could be due a direct interference of cAMP in cells that express opioid receptors. Moreover, the tolerance to opioid receptors changes the pathway signal transduction by the cAMP-dependent protein kinase [38,39]. Thus, if opioid receptors are expressed in salivary glands, probably morphine and CGP reduces the cAMP directly in these glands, which is a key mechanism that may be involved in reduced protein secretion in saliva. However, another explanation for morphine and CGP inhibitory effects on salivary protein concentration may be due to the opioid receptors presence that might have inhibited preganglionic or ganglionic sympathetic nerve projecting to salivary gland [40–42]. In both hypotheses, it seems clear that our study indicates inhibition of effects promoted by CGP and morphine by interaction with opioid receptors.

The reduction in salivary protein concentration and in Amide I/Amide II of submandibular promoted by opioid agonists is a characteristic of tissues that have low sympathetic activity and/or low glucose utilization, likely because they need to have a low energy status [43]. Besides, we also showed that both treatments are able to reduce glycogen, indicating influence of opioid system in glycogen metabolism on submandibular glands [44]. Specifically, the present study describes evacuated spaces (previously occupied by secretory acini) between acinar and ductal cells in glandular parenchyma of submandibular glands under morphine- and CGP-treatment. The fast (1h) effect of morphine and CGP suggests that it is not solely a consequence of reduction of parasympathetic/sympathetic activity. This is in agreement with
morphine-induced apoptosis of murine J774 cells mediated through TGF-beta [45]. Notably, this change is reinforced in morphine-treated mice. Considering the acute morphological changes with morphine and CGP, we can still propose induction of more profound morphological changes during chronic treatment. However, these effects could be promoted by the activation of kappa-, delta-, and/or mu-opioid-receptor by morphine and CGP in submandibular ganglion [18,24,46].

The CH₂ reduction in lipids [47] after morphine and CGP treatments suggests a decrease in lipid rafts that translocate proteins from intracellular structures to the plasma membrane [48], as well as decreasing energy status. Opioid agonists reduced PO₂ asymmetric of phospholipids, indicating damage in plasma membrane, which is also an apoptotic characteristic [49].

Considering the similar changes in salivary secretion and submandibular composition promoted by both therapeutic agents, we can consider that CGP have similar inhibitory effect on autonomic activity to salivary glands as described to morphine [18]. The CGP antinociceptive effect was antagonized by naloxone, a non-selective opioid receptor antagonist, suggesting that CGP effect may also occur through opioid receptor at the supraspinal level [24,50]. CGP increased neuronal activity in midbrain periaqueductal gray (PAG), a key relay station in the processing of nociceptive information in central nervous system [24,51] and that is interconnected with the hypothalamus [52]. Opioid receptors are spread in the hypothalamus [53] and these hypothalamic neurons may have inhibitory projections to superior salivary nucleus, from where ganglionic fibers of parasympathetic nervous system spread to submandibular glands [54–56]. Morphine also activates PAG [57], which suggest similar repercussion of CGP.

Therefore, we evaluated whether the salivary secretion reduction after treatment with CGP and morphine could be explained by acetylcholine decreased levels in the extracellular fluid, which could be demonstrated by acetylcholinesterase enzyme increased activity. Previous studies have shown an increase in brain acetylcholinesterase expression, 30 minutes after morphine injection (10 mg kg⁻¹ of morphine), indicating a higher enzyme activity and further acetylcholine degradation.[58]. However, another study showed that morphine chronic administration decreases acetylcholinesterase activity in the midbrain [59]. It is noteworthy that the acute effect of morphine and CGP on acetylcholinesterase activity in salivary gland has never been reported. Bearing in mind that the expected reduction of acetylcholine in synaptic cleft due to lower parasympathetic activity [18] is associated with similar acetylcholinesterase activity in submandibular glands after morphine and CGP treatment, it is expected that the acetylcholine presence in synaptic cleft can be further reduced due to the acetylcholine/ acetylcholinesterase ratio. Furthermore, these data emphasize that the reduction of pilocarpine-induced salivary secretion by morphine and CGP is likely to be prejunctional. Considering the present results and previous reports, we suggest a central and autonomic-pathway leading to changes in submandibular gland and hyposalivation by morphine and CGP (Fig 6).

To the best of our knowledge, this is the first report that demonstrates the salivary hyposecretion elicited by CGP, which is mediated by the opioid receptors’ system and such effect was reversed by naloxone. The present study also provides new evidence for an inhibitory morphine effect in pilocarpine-salivary secretion mediated by the opioid system in mice. Morphine and CGP also reduced salivary protein concentration and increased the lactate in submandibular gland and naloxone reverted both alterations. Morphine and CGP also reduced several infrared vibrational modes representing Amide I, Amide II, CH₂/CH₃, C = O, PO₂ asymmetric and PO₂ symmetric, which was blocked by pre-treatment with naloxone. To confirm the pathway to CGP effects, the in silico docking analysis demonstrate the polar contacts interaction between the CGP and opioid receptor Cys219 residue. Altogether, we showed that salivary hypofunction and glandular changes elicited by CGP may occur through opioid receptor
suggesting that opioid receptors blockage in superior cervical ganglion and submandibular ganglion may be a possible strategy to restore salivary secretion while maintaining antinociceptive effects due its effects in central nervous system.

**Supporting information**

S1 Fig. Effect of acute treatment with CGP and morphine on ionic composition present in stimulated saliva. (A-D) Inorganic elements of pilocarpine-stimulated saliva were evaluated the by fluorescent X-ray method. Concentrations of potassium (A), sulfur (B), chloride (C) and sodium (D) ions in the stimulated saliva remained unchanged after acute treatment with CGP and morphine. CGP, cyclo-Gly-Pro. Results are mean ± SEM of 6 animals; P>0.05 vs. vehicle. One-way ANOVA, Dunnett as post hoc test.

S2 Fig. Photomicrograph of submandibular gland from Swiss mice after 1h-treatment with vehicle, morphine and CGP. (A) The submandibular gland morphology is intact in vehicle-treated mice. (B) The acute treatment with morphine was able to increase the evacuated spaces (arrows) between the mucosal and serous acini in the submandibular gland.
parenchyma. (C) This change was not markedly evident after one hour of CGP treatment. Images are representative of 8 animals in each group. CGP, cyclo-Gly-Pro. Magnification, x400; scale bar, 20 μm.

(PPT)

S3 Fig. Activity of AChE enzyme in submandibular glands from Swiss mice after acute treatment with vehicle, morphine and CGP. CGP, cyclo-Gly-Pro. Results are mean ± SEM of 5 animals; \( p > 0.05 \) vs. vehicle. One-way ANOVA, Dunnett as post hoc test.

(PPT)

Acknowledgments

We would like to thank our collaborators at Rodent Vivarium Network (REBIR-UFAL) and the Dental Research Center in Biomechanics, Biomaterials and Cell Biology (CPbio).

Author Contributions

Conceptualization: Igor Santana Melo, Douglas Alexandre Alves, Emiliano de Oliveira Barreto, Robinson Sabino-Silva.

Data curation: Igor Santana Melo, Navylla Candeia-Medeiros, Jamylle Nunes Souza Ferro, Robinson Sabino-Silva.

Formal analysis: Igor Santana Melo, Jamylle Nunes Souza Ferro, Stephanie Wutke Oliveira, Douglas Alexandre Alves, Igor Andrade Santos, Ana Carolina Gomes Jardim, Walter Luiz Siqueira, Robinson Sabino-Silva.

Funding acquisition: Emiliano de Oliveira Barreto, Robinson Sabino-Silva.

Investigation: Igor Santana Melo, Navylla Candeia-Medeiros, Jamylle Nunes Souza Ferro, Polliane Maria Cavalcante-Araújo, Tales Lyra Oliveira, Cassio Eráclito Alves Santos, Leia Cardoso-Sousa, Emilia Maria Gomes Aguiar, Stephanie Wutke Oliveira, Renata Pereira Alves-Balvedi, Luciano Pereira Rodrigues, Douglas Alexandre Alves, Igor Andrade Santos, Ana Carolina Gomes Jardim, Walter Luiz Siqueira, Angelo Ricardo Fávaro Pipi, Robinson Sabino-Silva.

Methodology: Igor Santana Melo, Navylla Candeia-Medeiros, Jamylle Nunes Souza Ferro, Polliane Maria Cavalcante-Araújo, Tales Lyra Oliveira, Cassio Eráclito Alves Santos, Leia Cardoso-Sousa, Emilia Maria Gomes Aguiar, Stephanie Wutke Oliveira, Renata Pereira Alves-Balvedi, Luciano Pereira Rodrigues, Jandir M. Hickmann, Douglas Alexandre Alves, Igor Andrade Santos, Ana Carolina Gomes Jardim, Angelo Ricardo Fávaro Pipi, Luiz Ricardo Goulart, Emiliano de Oliveira Barreto, Robinson Sabino-Silva.

Project administration: Robinson Sabino-Silva.

Resources: Jandir M. Hickmann, Luiz Ricardo Goulart, Emiliano de Oliveira Barreto, Robinson Sabino-Silva.

Supervision: Ana Carolina Gomes Jardim, Walter Luiz Siqueira, Robinson Sabino-Silva.

Validation: Igor Santana Melo, Stephanie Wutke Oliveira, Robinson Sabino-Silva.

Visualization: Igor Santana Melo, Stephanie Wutke Oliveira, Olagide Wagner Castro, Douglas Alexandre Alves, Igor Andrade Santos, Ana Carolina Gomes Jardim, Walter Luiz Siqueira, Robinson Sabino-Silva.
Writing – original draft: Igor Santana Melo, Náylla Candeia-Medeiros, Jamylle Nunes Souza Ferro, Tales Lyra Oliveira, Olagide Wagner Castro, Luis Ricardo Goulart, Robinson Sabino-Silva.

Writing – review & editing: Igor Santana Melo, Stephanie Wutke Oliveira, Olagide Wagner Castro, Douglas Alexsander Alves, Igor Andrade Santos, Ana Carolina Gomes Jardim, Walter Luiz Siqueira, Luis Ricardo Goulart, Emiliano de Oliveira Barreto, Robinson Sabino-Silva.

References

1. Humphrey SP, Williamson RT. A review of saliva: Normal composition, flow, and function. J Prosthet Dent. 2001; 85: 162–169. https://doi.org/10.1067/mpr.2001.113778 PMID: 11208206

2. Aps JKM, Martens LC. Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int. 2005; 150: 119–131. https://doi.org/10.1016/j.forsciint.2004.10.026 PMID: 15944052

3. Ruhl S. The scientific exploration of saliva in the post-proteomic era: from database back to basic function. Expert Rev Proteomics. 2012; 9: 85–98. https://doi.org/10.1586/erp.11.80 PMID: 22292826

4. Emmelin N. Nerve interactions in salivary glands. J Dent Res. 1987; 66: 509–517. https://doi.org/10.1177/00220345870660022101 PMID: 3305629

5. Sabino-Silva R, Ceroni A, Koganezawa T, Michelini LC, Machado UF, Antunes VR. Baroreceptor-mediated activation of sympathetic nerve activity to salivary glands. Physiol Behav. 2012; 107: 390–6. https://doi.org/10.1016/j.physbeh.2012.09.012 PMID: 23022472

6. Proctor GB, Carpenter GH. Regulation of salivary gland function by autonomic nerves. Auton Neurosci Basic Clin. 2007; 133: 3–18. https://doi.org/10.1016/j.autneu.2006.10.006

7. Carpenter GH, Garrett JR, Hartley RH, Proctor GB. The influence of nerves on the secretion of immunoglobulin A into submandibular saliva in rats. J Physiol. 1998; 512 (Pt 2): 567–73. https://doi.org/10.1111/j.1469-7793.1998.567be.x

8. Garrett JR. The proper role of nerves in salivary secretion: a review. J Dent Res. 1987; 66: 387–397. https://doi.org/10.1177/00220345870660020201 PMID: 3305622

9. Sabino-Silva R, Alves-Wagner ABT, Buri G, Okamoto MM, Alves AS, Lima G, et al. SGLT1 protein expression in plasma membrane of acinar cells correlates with the sympathetic outflow to salivary glands in diabetic and hypertensive rats. Am J Physiol Endocrinol Metab. 2010; 299: E1028–37. https://doi.org/10.1152/ajpendo.00395.2010 PMID: 20841505

10. Renzi A, Colombari E, Mattos Filho TR, Silveira JE, Saad WA, Camargo LA, et al. Involvement of the central nervous system in the salivary secretion induced by pilocarpine in rats. J Dent Res. 1993; 72: 1481–4. https://doi.org/10.1177/00220345930720110401 PMID: 8227698

11. Meert TF, Vermeirsch H A. A preclinical comparison between different opioids: Antinociceptive versus adverse effects. Pharmacol Biochem Behav. 2005; 80: 309–326. https://doi.org/10.1016/j.pbb.2004.12.002 PMID: 15860184

12. Rougeot C, Robert F, Menz L, Bisson J-F, Messaoudi M. Systemically active human opioidphlin is a potent yet non-addictive analgesic without drug tolerance effects. J Physiol Pharmacol. 2010; 61: 483–90. Available: http://www.ncbi.nlm.nih.gov/pubmed/20814077 PMID: 20814077

13. COSMO A, DIAZIO;CHEN PIN-YANG. The Influence of Morphine on Excess Lactate Production, Anesthet Analg. 1971; 51: 211–216. Available: https://insights.ovid.com/pubmed?pmid=5102636 PMID: 5102636

14. Abdollahi M, Safarhamidi H. Protection by nitric oxide of morphine-induced inhibition of rat submandibular gland function. Pharmacol Res. 2002; 45: 87–92. https://doi.org/10.1016/s0031-6977(01)00312-7 PMID: 11846619

15. Hashemi N, Mohammadirad A, Bayrami Z, Khorasani R, Vosough S, Alihmadi A, et al. Restoration of morphine-induced alterations in rat submandibular gland function by N-methyl-D-aspartate agonist. Acta Biol Hung. 2006; 57: 283–294. https://doi.org/10.1556/Abiol.57.2006.3.2 PMID: 17048692

16. Crosara KTB, Zuanazzi D, Moffa EB, Xiao Y, Machado MA de AM, Siqueira WL. Revealing the Amylase Interactome in Whole Saliva Using Proteomic Approaches. Biomed Res Int. Hindwai; 2018; 2018: 1–15. https://doi.org/10.1155/2018/634695

17. Miwa Y, Saeki M, Yamaa A, Maeda S, Salto K. Effect of morphine on secretion of amylase from isolated parotid acini. Life Sci. 1996; 59: 1809–19. Available: http://www.ncbi.nlm.nih.gov/pubmed/8935708 doi: 10.1016/0024-3205(96)00524-3 PMID: 8935708
18. Endoh T, Suzuki T. The regulating manner of opioid receptors on distinct types of calcium channels in hamster submandibular ganglion cells. Arch Oral Biol. 1998; 43: 221–33. Available: http://www.ncbi.nlm.nih.gov/pubmed/9631175 doi: 10.1016/s0003-9969(98)00002-8 PMID: 9631175

19. Bowen SR, Carpenter FG. Morphine depression and tolerance of nerve-induced parotid secretion. Br J Pharmacol. 1979; 65: 7–13. Available: http://www.ncbi.nlm.nih.gov/pubmed/760892 doi: 10.1111/j.1476-5381.1979.tb17327.x PMID: 760892

20. Prasad C. Bioactive cyclic dipeptides. Peptides. 1995; 16: 151–64. Available: http://www.ncbi.nlm.nih.gov/pubmed/7716068 doi: 10.1016/0196-9781(94)00017-z PMID: 7716068

21. Burgos-Ramos E, Martos-Moreno G a, López MG, Herranz R, Aguado-Llera D, Egea J, et al. The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 beta modulation. J Neurochem. 2009; 109: 360–370. doi:JNC5980 [pii]https://doi.org/10.1111/j.1471-4159.2009.05980.x PMID: 19220704

22. Guan J, Gluckman PD. IGF-1 derived small neuropeptides and analogues: A novel strategy for the development of pharmaceuticals for neurological conditions. Br J Pharmacol. 2009; 157: 881–891. https://doi.org/10.1111/j.1476-5381.2009.02556.x PMID: 19438508

23. Hammond DL, Washington JD. Antagonism of L-baclofen-induced antinociception by CGP 35348 in the spinal cord of the rat. Eur J Pharmacol. 1993; 234: 255–62. Available: http://www.ncbi.nlm.nih.gov/pubmed/8387011 doi: 10.1016/0014-2999(93)90961-g PMID: 8387011

24. Ferro JN de S, de Aquino FLT, de Brito RG, Dos Santos PL, Quintans J de SS, de Souza LC, et al. Cyclo-Gly-Pro, a cyclic dipeptide, attenuates nociceptive behaviour and inflammatory response in mice. Clin Exp Pharmacol Physiol. 2015; 42: 1287–95. https://doi.org/10.1111/1440-1681.12480 PMID: 26277051

25. Charan J, Kantharia N. How to calculate sample size in animal studies? J Pharmcol Pharmacother. 2013; 4: 303. https://doi.org/10.4103/0976-500X.119726 PMID: 24250214

26. Zoukhri D, Kublin CL. Impaired Neurotransmitter Release from Lacrimal and Salivary Gland Nerves of a Murine Model of Sjogren’s Syndrome. Invest Ophthalmol Vis Sci. 2001; 42: 925–932. https://doi.org/10.1016/S0014-2999(01)70628-0 PMID: 11374068

27. Sabino-Silva R, Okamoto MM, David-Silva A, Mori RC, Freitas HS, Machado UF. Increased SGLT1 expression in salivary gland ductal cells correlates with hyposalivation in diabetic and hypertensive rats. Diabetol Metab Syndr. 2013; 5: 64. https://doi.org/10.1186/1758-5996-5-64 PMID: 24495577

28. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248–54. Available: http://www.ncbi.nlm.nih.gov/pubmed/1016/j.biot echadv.2011.08.021.Sec reted PMID: 11274068

29. Kurtova S, Shkurnikov M, Tonevitsky E, Artyushenko V, Tonevitsky A. Noninvasive biochemical monitoring of physiological stress by Fourier transform infrared saliva spectroscopy. Analyst. 2010; 135: 3183–92. https://doi.org/10.1039/c0an00529k PMID: 20953513

30. Zohdi V, Whelan DR, Wood BR, Pearson JT, Bambery KR, Black MJ. Importance of Tissue Preparation and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol. 2015; 172: 61. https://doi.org/10.1111/bjph.13334 PMID: 26114403

31. Christersson CE, Lindh L, Arnebrant T. Film-forming properties and viscosities of saliva substitutes and human whole saliva. Eur J Oral Sci. 2000; 108: 418–25. Available: http://www.ncbi.nlm.nih.gov/pubmed/11037758 doi: 10.1034/j.1600-0722.2000.108005418.x PMID: 11037758

32. Júnior PCC, Strixino JF, Raniero L. Analysis of saliva by Fourier transform infrared spectroscopy for diagnosis of physiological stress in athletes. Res Biomed Eng. 2015; 31: 116–124. https://doi.org/10.1590/2446-4740.0664

33. Zohdi V, Whelan DR, Wood BR, Pearson JT, Bambery KR, Black MJ. Importance of Tissue Preparation Methods in FTIR Micro-Spectroscopical Analysis of Biological Tissues: “Traps for New Users.” Tajmir-Riahi H-A, editor. PLoS One. Public Library of Science; 2015; 10: e0116491. https://doi.org/10.1371/journal.pone.0116491 PMID: 25710811

34. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. NIH Public Access; 2010; 31: 455–61. https://doi.org/10.1002/jcc.21334 PMID: 19495766

35. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SPA, Giembycz MA, et al. Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol. 2015; 172: 3461–71. https://doi.org/10.1111/bjph.12856 PMID: 26114403

36. Westerling D, Högglund P, Lundin S, Svedman P. Transdermal administration of morphine to healthy subjects. Br J Clin Pharmacol. 1994; 37: 571–576. https://doi.org/10.1111/j.1365-2125.1994.tb0306.x PMID: 7917776
37. Peres e Serra A, Ashmawi HA. Influence of naloxone and methysergide on the analgesic effects of low-level laser in an experimental pain model. Rev Bras Anestesiol. 2010; 60: 302–10. https://doi.org/10.1016/S0034-7094(10)70037-4 PMID: 20682161

38. Fundytus ME, Coderre TJ. Chronic inhibition of intracellular Ca2+ release or protein kinase C activation significantly reduces the development of morphine dependence. Eur J Pharmacol. 1996; 300: 173–181. doi:10.1016/0014-2999(95)00971-3 PMID: 8739205

39. Smith FL, Lohmann AB, Dewey WL. Involvement of phospholipid signal transduction pathways in morphine tolerance in mice. Br J Pharmacol. 1999; 128: 220–6. https://doi.org/10.1038/sbjjp.0702771 PMID: 10498855

40. TRENDLEBURG U. The action of morphine on the superior cervical ganglion and on the nictitating membrane of the cat. Br J Pharmacol Chemother. 1957; 12: 79–85. Available: http://www.ncbi.nlm.nih.gov/pubmed/13413156 doi: 10.1111/j.1476-5381.1957.tb01366.x PMID: 13413156

41. Zhang C, Bachoo M, Polosa C. The receptors activated by exogenous and endogenous opioids in the superior cervical ganglion of the cat. Brain Res. 1993; 622: 211–214. https://doi.org/10.1016/0006-8993(93)90821-4 PMID: 824358

42. Zhang C, Bachoo M, Morales M, Collier B, Polosa C. The site of inhibitory action of endogenous opioids in the superior cervical ganglion of the cat. Brain Res. Elsevier; 1995; 683: 59–64. https://doi.org/10.1016/0006-8993(95)00360-3

43. Isabella R, Raffone E. Does ovary need D-chiro-inositol? J Ovarian Res. 2012; 5: 14. https://doi.org/10.1186/1757-2215-5-14 PMID: 22587479

44. Gill A, Gao N, Lehman MA. Rapid activation of glycogen phosphorylase by the endoplasmic reticulum unfolded protein response. J Biol Chem. 2002; 277: 44747–53. https://doi.org/10.1074/jbc.M205001200 PMID: 12224745

45. Singhal PC, Kapasi AA, Franki N, Reddy K. Morphine-induced macrophage apoptosis: the role of transforming growth factor-beta. Immunology. 2000; 100: 57–62. Available: http://www.ncbi.nlm.nih.gov/pubmed/10809959 doi: 10.1046/j.1365-2567.2000.00007.x PMID: 10809959

46. Endoh T, Suzuki T. The effects of delta-opioid receptor agonists on synaptic transmission in hamster submandibular ganglion. Bull Tokyo Dent Coll. 1995; 36: 87–90. Available: http://www.ncbi.nlm.nih.gov/pubmed/8689748 PMID: 8689748

47. Huang N, Short M, Zhao J, Wang H, Lui H, Korbelik M, et al. Full range characterization of the Raman spectra of organs in a murine model. Opt Express. 2011; 19: 22892–909. Available: http://www.ncbi.nlm.nih.gov/pubmed/21234205 doi: 10.1016/j.ramanlett.2011.09.001 PMID: 21234205

48. Feng S, Huang S, Lin D, Chen G, Xu Y, Li Y, et al. Surface-enhanced Raman spectroscopy of saliva proteins for the noninvasive differentiation of benign and malignant breast tumors. Int J Nanomedicine. 2015; 10: 537–47. https://doi.org/10.2147/IJN.S71811 PMID: 25609959

49. Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival—unraveling mechanisms and revealing new indications. Pharmacol Rev. 2004; 56: 351–69. https://doi.org/10.1124/pr.56.3.2 PMID: 15317908

50. Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: Specificity, recruitment and plasticity. Brain Res Rev. 2009; 60: 214–25. https://doi.org/10.1016/j.brainresrev.2008.12.009 PMID: 19146877

51. Bandler R, Shipley MT. Columnar organization in the midbrain periaqueductal gray: modules for emotional expression? Trends Neurosci. 1994; 17: 379–89. Available: http://www.ncbi.nlm.nih.gov/pubmed/7817403 doi: 10.1016/0166-2236(94)90047-7 PMID: 7817403

52. Yaksh TL, Yeung JC, Rudy TA. Systematic examination in the rat brain sites sensitive to the direct application of morphine: observation of differential effects within the periaqueductal gray. Brain Res. 1976; 114: 83–103. Available: http://www.ncbi.nlm.nih.gov/pubmed/1963546 doi: 10.1016/0006-8993(76)91009-x PMID: 1963546

53. Yaksh TL. Spinal systems and pain processing: Development of novel analgesic drugs with mechanism-defined models. Trends Pharmacol Sci. 1999; 20: 329–337. https://doi.org/10.1016/S0165-6147(99)01370-X PMID: 10431212

54. Segal K, Lisyniansky I, Nageris B, Feinmesser R. Parasympathetic innervation of the salivary glands. Oper Tech Otolaryngol Neck Surg. Elsevier; 1996; 7: 333–338. https://doi.org/10.1016/S1043-1810(96)80005-4 PMID: 9044994

55. Lin LH, Agassandian K, Fujiyama F, Kaneko T, Talman WT. Evidence for a glutamatergic input to pontine preganglionic neurons of the superior salivatory nucleus in rat. J Chem Neuroanat. 2003; 25: 261–268. doi:10.1016/S0891-0618(03)00033-4 PMID: 12842271

56. Mitoh Y, Funahashi M, Kobashi M, Matsuo R. Excitatory and inhibitory postsynaptic currents of the superior salivatory nucleus innervating the salivary glands and tongue in the rat. Brain Res. 2004; 999: 62–72. https://doi.org/10.1016/j.brainres.2003.11.053 PMID: 14746922
57. Hao S, Liu S, Zheng X, Zheng W, Ouyang H, Mata M, et al. The role of TNFα in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. Neuropsychopharmacology. 2011; 36: 664–76. https://doi.org/10.1038/npp.2010.197 PMID: 21068718

58. Mohanakumar KP, Sood PP. Acetylcholinesterase changes in the central nervous system of mice during the development of morphine tolerance addiction and withdrawal. Brain Res Bull. 1983; 10: 589–96. Available: http://www.ncbi.nlm.nih.gov/pubmed/6683583 doi: 10.1016/0361-9230(83)90026-6 PMID: 6683583

59. Neugebauer NM, Einstein EB, Lopez MB, McClure-Begley TD, Mineur YS, Picciotto MR. Morphine dependence and withdrawal induced changes in cholinergic signaling. Pharmacol Biochem Behav. 2013; 109: 77–83. https://doi.org/10.1016/j.pbb.2013.04.015 PMID: 23651795